JP2015131853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015131853A5 JP2015131853A5 JP2015085594A JP2015085594A JP2015131853A5 JP 2015131853 A5 JP2015131853 A5 JP 2015131853A5 JP 2015085594 A JP2015085594 A JP 2015085594A JP 2015085594 A JP2015085594 A JP 2015085594A JP 2015131853 A5 JP2015131853 A5 JP 2015131853A5
- Authority
- JP
- Japan
- Prior art keywords
- layer
- tablet
- tablet according
- sodium
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 5
- 208000031886 HIV Infections Diseases 0.000 claims 5
- 208000037357 HIV infectious disease Diseases 0.000 claims 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 5
- 229960001681 croscarmellose sodium Drugs 0.000 claims 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 5
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 claims 5
- 229960002814 rilpivirine Drugs 0.000 claims 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 4
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 4
- 229960000366 emtricitabine Drugs 0.000 claims 4
- 229960001021 lactose monohydrate Drugs 0.000 claims 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 239000002610 basifying agent Substances 0.000 claims 2
- 229940057948 magnesium stearate Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002897 polymer film coating Substances 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 claims 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 239000000908 ammonium hydroxide Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- -1 dihydroaluminum Chemical compound 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- MSJMDZAOKORVFC-UAIGNFCESA-L disodium maleate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C/C([O-])=O MSJMDZAOKORVFC-UAIGNFCESA-L 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- 229940074404 sodium succinate Drugs 0.000 claims 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 1
- 239000001433 sodium tartrate Substances 0.000 claims 1
- 229960002167 sodium tartrate Drugs 0.000 claims 1
- 235000011004 sodium tartrates Nutrition 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41560010P | 2010-11-19 | 2010-11-19 | |
| US61/415,600 | 2010-11-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013540085A Division JP2014500261A (ja) | 2010-11-19 | 2011-11-18 | リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015131853A JP2015131853A (ja) | 2015-07-23 |
| JP2015131853A5 true JP2015131853A5 (OSRAM) | 2016-01-07 |
| JP6138851B2 JP6138851B2 (ja) | 2017-05-31 |
Family
ID=45094284
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013540085A Withdrawn JP2014500261A (ja) | 2010-11-19 | 2011-11-18 | リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物 |
| JP2015085594A Active JP6138851B2 (ja) | 2010-11-19 | 2015-04-20 | リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013540085A Withdrawn JP2014500261A (ja) | 2010-11-19 | 2011-11-18 | リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物 |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US10857102B2 (OSRAM) |
| EP (2) | EP2826466A1 (OSRAM) |
| JP (2) | JP2014500261A (OSRAM) |
| KR (1) | KR101923103B1 (OSRAM) |
| CN (2) | CN106511357A (OSRAM) |
| AP (1) | AP3816A (OSRAM) |
| AR (2) | AR084500A1 (OSRAM) |
| AU (3) | AU2011329642B2 (OSRAM) |
| BR (1) | BR112013012245B1 (OSRAM) |
| CA (1) | CA2818097C (OSRAM) |
| CL (1) | CL2013001402A1 (OSRAM) |
| CO (1) | CO6761300A2 (OSRAM) |
| CR (1) | CR20130293A (OSRAM) |
| DK (1) | DK2640362T4 (OSRAM) |
| EA (2) | EA025852B1 (OSRAM) |
| EC (2) | ECSP13012700A (OSRAM) |
| ES (1) | ES2524408T5 (OSRAM) |
| HK (1) | HK1206592A1 (OSRAM) |
| HR (1) | HRP20140946T1 (OSRAM) |
| IL (1) | IL226300B (OSRAM) |
| MA (1) | MA34735B1 (OSRAM) |
| ME (1) | ME01980B (OSRAM) |
| MX (1) | MX347512B (OSRAM) |
| MY (1) | MY185604A (OSRAM) |
| NZ (1) | NZ610729A (OSRAM) |
| PE (3) | PE20211657A1 (OSRAM) |
| PH (1) | PH12013501002A1 (OSRAM) |
| PL (1) | PL2640362T5 (OSRAM) |
| PT (1) | PT2640362E (OSRAM) |
| RS (1) | RS53691B1 (OSRAM) |
| SG (3) | SG10201912527XA (OSRAM) |
| SM (1) | SMT201400150B (OSRAM) |
| TW (1) | TWI556840B (OSRAM) |
| UA (1) | UA114075C2 (OSRAM) |
| WO (1) | WO2012068535A1 (OSRAM) |
| ZA (1) | ZA201304481B (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040224917A1 (en) | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| ES2524408T5 (es) | 2010-11-19 | 2022-04-25 | Gilead Sciences Inc | Composiciones terapéuticas que comprenden rilpivirina HCl y tenofovir disoproxil fumarato |
| UA115311C2 (uk) | 2011-08-16 | 2017-10-25 | Гіліад Сайєнсіз, Інк. | Геміфумарат тенофовіру алафенаміду |
| CA2779052A1 (en) * | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
| DK3067358T3 (da) | 2012-12-21 | 2019-11-04 | Gilead Sciences Inc | Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse |
| WO2015014737A1 (en) * | 2013-07-29 | 2015-02-05 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Multilayer tablet formulations comprising tenofovir and entecavir |
| CZ2013985A3 (cs) * | 2013-12-09 | 2015-06-17 | Zentiva, K.S. | Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát |
| WO2015152433A1 (en) * | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| US9839212B2 (en) | 2015-04-16 | 2017-12-12 | Bio-Lab, Inc. | Multicomponent and multilayer compacted tablets |
| KR20170003063A (ko) * | 2015-06-30 | 2017-01-09 | 한미약품 주식회사 | 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법 |
| CA2921336A1 (en) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| BR102016026127A2 (pt) | 2015-11-09 | 2017-05-16 | Gilead Sciences Inc | composições terapêuticas para o tratamento do vírus da imunodeficiência humana |
| US20190060325A1 (en) * | 2016-04-08 | 2019-02-28 | Shionogi & Co., Ltd. | Stabilized solid dosage form |
| TR201617448A2 (tr) * | 2016-11-29 | 2018-06-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler |
| US10561614B2 (en) * | 2017-01-27 | 2020-02-18 | Steerlife India Private Limited | Tenofovir granules |
| JP7287906B2 (ja) * | 2017-06-30 | 2023-06-06 | ヴィーブ ヘルスケア カンパニー | 組み合わせ並びにその使用及びそれによる治療 |
| PL3706762T3 (pl) | 2017-12-07 | 2025-02-10 | Emory University | N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe |
| MA56449A (fr) * | 2019-07-03 | 2022-05-11 | Janssen Sciences Ireland Unlimited Co | Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine |
| CN112137981A (zh) * | 2020-11-02 | 2020-12-29 | 成都晶富医药科技有限公司 | 富马酸丙酚替诺福韦片及其制备工艺 |
| WO2024211882A1 (en) * | 2023-04-07 | 2024-10-10 | Navinta, Llc | Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents |
| CN119174735A (zh) * | 2024-09-03 | 2024-12-24 | 安徽贝克生物制药有限公司 | 一种含利匹韦林的复方片及制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ250842A (en) | 1991-02-22 | 1996-03-26 | Univ Emory | Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc) |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| WO2003045327A2 (en) | 2001-11-27 | 2003-06-05 | Bristol-Myers Squibb Company | Efavirenz tablet formulation having unique biopharmaceutical characteristics |
| US20040224917A1 (en) | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| ES2371442T7 (es) | 2004-09-02 | 2022-05-12 | Janssen Pharmaceutica Nv | Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo |
| CA2577288C (en) | 2004-09-02 | 2010-11-30 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| CA2625776A1 (en) | 2005-10-14 | 2007-04-26 | Microdose Technologies, Inc. | Pharmaceutical packaging of an oral dosage combination |
| RU2008128424A (ru) | 2005-12-14 | 2010-01-20 | Сипла Лимитед (In) | Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы |
| ES2602784T3 (es) * | 2007-02-23 | 2017-02-22 | Gilead Sciences, Inc. | Moduladores de las propiedades farmacocinéticas de los agentes terapéuticos |
| US20080286344A1 (en) | 2007-05-16 | 2008-11-20 | Olivia Darmuzey | Solid form |
| WO2008140461A1 (en) | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
| CN101778855A (zh) * | 2007-05-22 | 2010-07-14 | 阿尔迪默菲克斯技术有限责任公司 | 替诺福韦酯半富马酸共晶体 |
| WO2009037449A1 (en) | 2007-09-18 | 2009-03-26 | Cipla Limited | Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors |
| WO2009106960A2 (en) | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable compositions of lamivudine, tenofovir and efavirenz |
| HRP20151357T1 (hr) | 2008-05-02 | 2016-01-29 | Gilead Sciences, Inc. | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa |
| EA021313B1 (ru) | 2009-02-06 | 2015-05-29 | Джилид Сайэнс, Инк. | Таблетки для комбинированной терапии |
| ES2730805T3 (es) | 2009-09-21 | 2019-11-12 | Gilead Sciences Inc | Análogos de carba-nucleósido sustituido por 2'-fluoro para el tratamiento antiviral |
| WO2011077100A1 (en) | 2009-12-24 | 2011-06-30 | Cipla Limited | Antiretroviral composition |
| ES2524408T5 (es) | 2010-11-19 | 2022-04-25 | Gilead Sciences Inc | Composiciones terapéuticas que comprenden rilpivirina HCl y tenofovir disoproxil fumarato |
-
2011
- 2011-11-18 ES ES11791161T patent/ES2524408T5/es active Active
- 2011-11-18 RS RS20140668A patent/RS53691B1/sr unknown
- 2011-11-18 SG SG10201912527XA patent/SG10201912527XA/en unknown
- 2011-11-18 SG SG10201509521WA patent/SG10201509521WA/en unknown
- 2011-11-18 MY MYPI2016001764A patent/MY185604A/en unknown
- 2011-11-18 SG SG2013038484A patent/SG190333A1/en unknown
- 2011-11-18 DK DK11791161.0T patent/DK2640362T4/da active
- 2011-11-18 JP JP2013540085A patent/JP2014500261A/ja not_active Withdrawn
- 2011-11-18 TW TW100142311A patent/TWI556840B/zh active
- 2011-11-18 CN CN201610900183.1A patent/CN106511357A/zh active Pending
- 2011-11-18 EP EP14183494.5A patent/EP2826466A1/en not_active Withdrawn
- 2011-11-18 US US13/988,072 patent/US10857102B2/en active Active
- 2011-11-18 CA CA2818097A patent/CA2818097C/en active Active
- 2011-11-18 AU AU2011329642A patent/AU2011329642B2/en active Active
- 2011-11-18 PE PE2021000720A patent/PE20211657A1/es unknown
- 2011-11-18 PL PL11791161T patent/PL2640362T5/pl unknown
- 2011-11-18 PH PH1/2013/501002A patent/PH12013501002A1/en unknown
- 2011-11-18 EA EA201390651A patent/EA025852B1/ru unknown
- 2011-11-18 PE PE2016002828A patent/PE20170521A1/es unknown
- 2011-11-18 UA UAA201306403A patent/UA114075C2/uk unknown
- 2011-11-18 CN CN201180063666.6A patent/CN103491948B/zh active Active
- 2011-11-18 NZ NZ610729A patent/NZ610729A/en unknown
- 2011-11-18 BR BR112013012245-5A patent/BR112013012245B1/pt active IP Right Grant
- 2011-11-18 MX MX2013005669A patent/MX347512B/es active IP Right Grant
- 2011-11-18 KR KR1020137015719A patent/KR101923103B1/ko active Active
- 2011-11-18 PE PE2013001214A patent/PE20140163A1/es not_active Application Discontinuation
- 2011-11-18 EA EA201691695A patent/EA201691695A1/ru unknown
- 2011-11-18 WO PCT/US2011/061515 patent/WO2012068535A1/en not_active Ceased
- 2011-11-18 PT PT117911610T patent/PT2640362E/pt unknown
- 2011-11-18 HR HRP20140946AT patent/HRP20140946T1/hr unknown
- 2011-11-18 AR ARP110104318A patent/AR084500A1/es not_active Application Discontinuation
- 2011-11-18 EP EP11791161.0A patent/EP2640362B2/en active Active
- 2011-11-18 ME MEP-2014-150A patent/ME01980B/me unknown
- 2011-11-18 AP AP2013006931A patent/AP3816A/en active
-
2013
- 2013-05-12 IL IL226300A patent/IL226300B/en active IP Right Grant
- 2013-05-17 CL CL2013001402A patent/CL2013001402A1/es unknown
- 2013-05-28 CO CO13130615A patent/CO6761300A2/es unknown
- 2013-06-14 MA MA36010A patent/MA34735B1/fr unknown
- 2013-06-17 CR CR20130293A patent/CR20130293A/es unknown
- 2013-06-18 ZA ZA2013/04481A patent/ZA201304481B/en unknown
- 2013-06-18 EC ECSP13012700 patent/ECSP13012700A/es unknown
-
2014
- 2014-03-21 HK HK15106347.0A patent/HK1206592A1/en unknown
- 2014-10-16 SM SM201400150T patent/SMT201400150B/xx unknown
-
2015
- 2015-04-20 JP JP2015085594A patent/JP6138851B2/ja active Active
-
2016
- 2016-07-29 AU AU2016208417A patent/AU2016208417B2/en active Active
-
2018
- 2018-04-16 AU AU2018202635A patent/AU2018202635A1/en not_active Abandoned
-
2019
- 2019-10-30 EC ECSENADI201978196A patent/ECSP19078196A/es unknown
-
2020
- 2020-11-19 AR ARP200103214A patent/AR123409A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015131853A5 (OSRAM) | ||
| HRP20140946T1 (hr) | Terapeutske kompozicije koje sadrže rilpivirin hcl i tenovofir dizoproksil fumarat | |
| JP2017057230A5 (OSRAM) | ||
| JP5509086B2 (ja) | フィルムコーティング割線錠剤 | |
| JP2015506377A5 (OSRAM) | ||
| JP2016518452A5 (OSRAM) | ||
| JP2015038149A5 (OSRAM) | ||
| JP2017528507A5 (OSRAM) | ||
| NZ729172A (en) | Combination formulation of two antiviral compounds | |
| JP2017105793A5 (OSRAM) | ||
| JP2016163571A5 (OSRAM) | ||
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| JP2006516570A5 (OSRAM) | ||
| JP2017506624A5 (OSRAM) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| AU2016231883B2 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| RU2019140298A (ru) | Комбинация, ее применение и способы лечения с использованием указанной комбинации | |
| KR101658275B1 (ko) | 에스오메프라졸 함유 소형 의약정제 | |
| JP2018530566A5 (OSRAM) | ||
| JP2019533672A5 (OSRAM) | ||
| FI3448430T3 (fi) | Asetyylikoleeniesteraasi-inhibiittorin ja idalopirdiinin käyttö Parkinsonin taudin potilaiden kaatumisten vähentämiseksi | |
| RU2018128416A (ru) | Способ получения фармацевтической композиции, включающей производное хинолина или его соль | |
| RU2007125596A (ru) | Комбинированный противотуберкулезный препарат | |
| JP2022031068A (ja) | ラメルテオン含有被覆錠 | |
| JP2019034929A (ja) | エソメプラゾールマグネシウム水和物を含有する腸溶性コーティング製剤、およびその製造方法 |